Capital World Investors
BMRN icon

Capital World Investors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Capital World Investors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-3
Closed – – 532
2020
Q1 		$0 Sell
3
-2,493,175
-100% -$215M ﹤0.01% 526
2019
Q4 		$211M Buy
2,493,178
+1,392
+0.1% +$105K 0.05% 247
2019
Q3 		$168M Buy
2,491,786
+65,704
+3% +$5.06M 0.04% 257
2019
Q2 		$208M Buy
2,426,082
+872,055
+56% +$74.6M 0.05% 245
2019
Q1 		$138M Buy
1,554,027
+336,000
+28% +$31.1M 0.03% 275
2018
Q4 		$104M Sell
1,218,027
-1,243,814
-51% -$118M 0.03% 281
2018
Q3 		$239M Buy
2,461,841
+628,738
+34% +$62.8M 0.06% 227
2018
Q2 		$173M Buy
1,833,103
+158,184
+9% +$13.9M 0.04% 257
2018
Q1 		$136M Buy
1,674,919
+220,309
+15% +$18.9M 0.03% 262
2017
Q4 		$130M Buy
1,454,610
+227,456
+19% +$19.8M 0.03% 277
2017
Q3 		$114M Buy
1,227,154
+813,133
+196% +$71.9M 0.03% 278
2017
Q2 		$37.6M Buy
414,021
+3,286
+0.8% +$299K 0.01% 368
2017
Q1 		$36.1M Buy
+410,735
New +$36.5M 0.01% 377
2014
Q2 		– Sell
-1,120,000
Closed -$76.4M – 517
2014
Q1 		$76.4M Sell
1,120,000
-350,000
-24% -$25.8M 0.02% 316
2013
Q4 		$103M Sell
1,470,000
-140,700
-9% -$9.56M 0.03% 293
2013
Q3 		$116M Sell
1,610,700
-2,067,525
-56% -$137M 0.04% 287
2013
Q2 		$205M Buy
+3,678,225
New +$229M 0.07% 230

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Capital World Investors's BMRN Position: Q2 2020 in Review

Capital World Investors sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2020, closing a stake of 3 shares.

Capital World Investors first reported a position in BMRN in Q2 2013 and held it in 17 quarters. The position peaked at $239M in Q3 2018. 527 funds tracked by Wall St. Rank hold BMRN as of Q2 2020.

  • Capital World Investors reported no remaining BioMarin Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Capital World Investors sold 3 BioMarin Pharmaceuticals shares in Q2 2020.
  • Capital World Investors first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 17 quarters.
  • Capital World Investors's BioMarin Pharmaceuticals position peaked at $239M in Q3 2018.
  • 527 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2020.

Based on Capital World Investors's 13F filing for Q2 2020, filed 14 Aug 2020.